Compositions and methods for mucosal delivery of agents are provided. The emulsion compositions are intended for administration to a mucosal surface, such as oral, gastrointestinal and nasal mucosa. The emulsion compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.

The present invention relates to a probiotic Lactobacillus reuteri strain obtained by growing the bacteria in a medium comprising galacto-oligosaccharides (GOS), so called pre-conditioning. The pre-conditioning method provides boosting effects of the probiotic L. reuteri strain, such as improved mineral absorption, in the gastrointestinal tract. The invention comprises methods for manufacturing and cultivating probiotic Lactobacillus reuteri strains, and products and first and second medical uses of such strains.

The present invention relates to the use of maltodextrin as an excipient. In particular, the present invention relates to the use of maltodextrin as an excipient in probiotic formulations.

The present invention also relates to a method to provide a probiotics formulation with improved dispersibility and/or shelf life comprising adding maltodextrin to probiotic formulations.

The present invention relates to the use of maltodextrin as an excipient. In particular, the present invention relates to the use of maltodextrin as an excipient in probiotic formulations.

The present invention also relates to a method to provide a probiotics formulation with improved dispersibility and/or shelf life comprising adding maltodextrin to probiotic formulations.

Disclosed are a yoghurt for regulating intestinal tract, preparation method therefor, and use thereof, where the yogurt is prepared from raw materials comprising the following parts by weight: 90-97 parts of raw milk, Lactobacillus gasseri of (0.7-5)×10.sup.8 CFU/100 g raw milk, Streptococcus thermophilus of (0.1-9)×10.sup.10 CFU/100 g raw milk, Lactobacillus bulgaricus of (0.1-9)×10.sup.10 CFU/100 g raw milk, Lactobacillus acidophilus of (0.5-7)×10.sup.8 CFU/100 g raw milk, Lactobacillus plantarum of (0.5-7)×10.sup.8 CFU/100 g raw milk, Lactobacillus paracasei of (0.1-9)×10.sup.7 CFU/100 g raw milk, and other probiotics, and prebiotics such as inulin. The yogurt may regulate the balance of intestinal flora and prevent constipation and gestational diabetes in overweight and/or obese pregnant women during the gestation period.

The present invention provides a dried fish fermentation process and a starter culture development technology. A mixed starter culture including Bifidobacterium species, Lactobacillus acidophilus, Lactobacillus casei, Streptococcus thermophilus and Bifidobacterium lactis is prepared for the mixed fermentation of a dried fish; and salt content in the dried fish is controlled to control a proportional relation of flora in the mixed starter culture and to optimize the fermentation process, thereby preparing more fresh and delicious, fishy-free, more soft and delicate dried fish. Therefore, the dried fish is more popular with consumers.

Disclosed herein is an isolated strain of Lactobacillus acidophilus TW01, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33990. Also disclosed herein are uses of the isolated strain of Lactobacillus acidophilus TW01 for alleviating an inflammation-related disorder and for improving gut health.

Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals such as humans are disclosed. The supplement is in a tablet or capsule form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal such as a human with the supplement at least once daily.

A combination of herbal extracts and a probiotic supplement and formulated as a dietary supplement helps mitigate symptoms of bronchopulmonary disease in conjunction with the anti-inflammatory mechanisms of the probiotics. Provided are embodiments of a probiotic nutraceutical composition that delivers 3 strains of Lactobacillus spp. to the gut lining of human subjects to reduce neutrophilic inflammation as a result of or causative agent of bronchopulmonary disease. In addition to the three Lactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.